In this video, Dr. Sanjay Kalra, DM (Endocrinology), elaborates the key aspects leading to the right choice of an antidiabetic drug regimen. As recommended by clinical association like AACE, treatment for diabetic patients with more than 7.5 % HbA1c at presentation should be initiated with a combination therapy than monotherapy. In this video, Dr.
Kalra speaks about safety, efficacy, and tolerability of linagliptin and metformin combination therapy. He detailed how it can help the clinician to ease their decision making and troubleshooting in antidiabetic therapy. What is your preferred choice of initial therapy for type 2 diabetes patients with HbA1c level more than 7.5% at presentation?
